Mirum Pharmaceuticals, Inc. Stock-Based Compensation
Mirum Pharmaceuticals, Inc. (MIRM) reported Stock-Based Compensation of $66.78 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $30.57M, a 65.55% increase year-over-year.
- Mirum Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $36.20M, a 129.08% increase year-over-year.
- Mirum Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $19.03M, a 43.58% increase year-over-year.
- Mirum Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $18.13M, a 52.23% increase year-over-year.
- Mirum Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $71.42M, a 47.44% increase from fiscal 2024.
- Mirum Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $48.44M, a 38.32% increase from fiscal 2023.
- Mirum Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $35.02M, a 29.68% increase from fiscal 2022.
- Mirum Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $27.01M, a 16.98% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 8 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $30.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $66.78M 10-Q · filed 2026-08-05 | $85.80M derived: sum of 3 quarters · filed 2026-08-05 | $103.93M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | $36.20M 10-Q · filed 2026-05-06 | $55.23M derived: sum of 2 quarters · filed 2026-05-06 | $73.36M derived: sum of 3 quarters · filed 2026-05-06 | $91.82M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | $19.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $37.15M derived: sum of 2 quarters · filed 2026-02-25 | $55.62M derived: sum of 3 quarters · filed 2026-08-05 | $71.42M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $18.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $36.59M derived: sum of 2 quarters · filed 2026-08-05 | $52.40M 10-Q · filed 2025-11-04 | $65.65M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | $18.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $34.27M 10-Q · filed 2026-08-05 | $47.52M derived: sum of 3 quarters · filed 2026-08-05 | $59.43M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $15.80M 10-Q · filed 2026-05-06 | $29.05M derived: sum of 2 quarters · filed 2026-05-06 | $40.96M derived: sum of 3 quarters · filed 2026-05-06 | $52.80M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $13.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $25.16M derived: sum of 2 quarters · filed 2026-02-25 | $36.99M derived: sum of 3 quarters · filed 2026-02-25 | $48.44M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $11.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $23.74M derived: sum of 2 quarters · filed 2025-11-04 | $35.19M 10-Q · filed 2025-11-04 | $44.91M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-06-30 | $11.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $23.29M 10-Q · filed 2025-08-06 | $33.01M derived: sum of 3 quarters · filed 2026-02-25 | $41.39M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2024-03-31 | $11.45M 10-Q · filed 2025-05-07 | $21.17M derived: sum of 2 quarters · filed 2026-02-25 | $29.55M derived: sum of 3 quarters · filed 2026-02-25 | $37.91M derived: sum of 4 quarters · filed 2026-02-25 | |
| 2023-12-31 | $9.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $18.11M derived: sum of 2 quarters · filed 2026-02-25 | $26.46M derived: sum of 3 quarters · filed 2026-02-25 | $35.02M 10-K · filed 2026-02-25 | |
| 2023-09-30 | $8.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $16.74M derived: sum of 2 quarters · filed 2024-11-12 | $25.30M 10-Q · filed 2024-11-12 | $32.20M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-06-30 | $8.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $16.92M 10-Q · filed 2024-08-07 | $23.81M derived: sum of 3 quarters · filed 2025-02-26 | $30.55M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2023-03-31 | $8.56M 10-Q · filed 2024-05-08 | $15.46M derived: sum of 2 quarters · filed 2025-02-26 | $22.19M derived: sum of 3 quarters · filed 2025-02-26 | $29.01M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2022-12-31 | $6.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $13.63M derived: sum of 2 quarters · filed 2025-02-26 | $20.45M derived: sum of 3 quarters · filed 2025-02-26 | $27.01M 10-K · filed 2025-02-26 | |
| 2022-09-30 | $6.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $13.55M derived: sum of 2 quarters · filed 2023-11-02 | $20.11M 10-Q · filed 2023-11-02 | $25.68M derived: sum of 4 quarters · filed 2024-03-15 | |
| 2022-06-30 | $6.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $13.38M 10-Q · filed 2023-08-07 | $18.94M derived: sum of 3 quarters · filed 2024-03-15 | $26.36M derived: sum of 4 quarters · filed 2024-03-15 | |
| 2022-03-31 | $6.56M 10-Q · filed 2023-05-04 | $12.13M derived: sum of 2 quarters · filed 2024-03-15 | $19.54M derived: sum of 3 quarters · filed 2024-03-15 | $24.36M derived: sum of 4 quarters · filed 2024-03-15 | |
| 2021-12-31 | $5.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $12.98M derived: sum of 2 quarters · filed 2024-03-15 | $17.80M derived: sum of 3 quarters · filed 2024-03-15 | $23.09M 10-K · filed 2024-03-15 | |
| 2021-09-30 | $7.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $12.24M derived: sum of 2 quarters · filed 2022-11-09 | $17.52M 10-Q · filed 2022-11-09 | $21.10M derived: sum of 4 quarters · filed 2022-11-09 | |
| 2021-06-30 | $4.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $10.11M 10-Q · filed 2022-08-04 | $13.69M derived: sum of 3 quarters · filed 2022-08-04 | $17.11M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | $5.29M 10-Q · filed 2022-05-05 | $8.86M derived: sum of 2 quarters · filed 2022-05-05 | $12.29M derived: sum of 3 quarters · filed 2022-05-05 | $15.27M derived: sum of 4 quarters · filed 2022-05-05 | |
| 2020-12-31 | $3.58M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $7.01M derived: sum of 2 quarters · filed 2022-03-09 | $9.98M derived: sum of 3 quarters · filed 2022-03-09 | $12.55M 10-K · filed 2022-03-09 | |
| 2020-09-30 | $3.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $6.40M derived: sum of 2 quarters · filed 2021-11-15 | $8.97M 10-Q · filed 2021-11-15 | $11.04M derived: sum of 4 quarters · filed 2021-11-15 | |
| 2020-06-30 | $2.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $5.55M 10-Q · filed 2021-08-05 | $7.61M derived: sum of 3 quarters · filed 2021-08-05 | $9.76M derived: sum of 4 quarters · filed 2021-08-05 | |
| 2020-03-31 | $2.57M 10-Q · filed 2021-05-06 | $4.64M derived: sum of 2 quarters · filed 2021-05-06 | $6.78M derived: sum of 3 quarters · filed 2021-05-06 | $8.43M derived: sum of 4 quarters · filed 2021-05-06 | |
| 2019-12-31 | $2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $4.21M derived: sum of 2 quarters · filed 2021-03-09 | $5.85M derived: sum of 3 quarters · filed 2021-03-09 | $6.07M 10-K · filed 2021-03-09 | |
| 2019-09-30 | $2.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $3.79M derived: sum of 2 quarters · filed 2020-11-12 | $4.00M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $1.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $1.86M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $218.00K 10-Q · filed 2020-05-07 | ||||
| 2018-12-31 | $34.00K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |